Vital Therapies reported $88.08M in Cash and Equivalent for its second fiscal quarter of 2022.

Trading Economics members can view, download and compare data from nearly 200 countries, including more than 20 million economic indicators, exchange rates, government bond yields, stock indexes and commodity prices.

The Trading Economics Application Programming Interface (API) provides direct access to our data. It allows API clients to download millions of rows of historical data, to query our real-time economic calendar, subscribe to updates and receive quotes for currencies, commodities, stocks and bonds.

Please Paste this Code in your Website
Cash And Equivalent Change
Biomarin Pharmaceutical BMRN:US $ 619.8M 14.36M
Dynavax Technologies DVAX:US $ 249.09M 69.67M
Enanta Pharmaceuticals ENTA:US $ 28.37M 12.62M
Epizyme EPZM:US $ 71.07M 6.36M
Insmed INSM:US $ 416.08M 99.63M
Intercept Pharmaceuticals ICPT:US $ 58.02M 9.7M
Mirati Therapeutics MRTX:US $ 245.51M 47.91M
Omeros OMER:US $ 14.14M 5.17M
Orasure Technologies OSUR:US $ 66.16M 4.56M
Quidel QDEL:US $ 379M 896.54M
Regulus Therapeutics RGLS:US $ 35.12M 18.78M
Revance Therapeutics RVNC:US $ 69.42M 128.94M
Ultragenyx Pharmaceutical RARE:US $ 159.87M 5.88M
United Therapeutics UTHR:US $ 795.2M 18.1M
Vital Therapies VTL:US $ 88.08M 7.63M